NEWS & PUBLICATIONS
JUST PUBLISHED - QUADRAMET CLINICAL SAFETY UPDATES:
Phase I Study of Samarium - 153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer
-Morris MJ, et al. J Clin Oncol. May 20, 2009; Vol.27, No 15
Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer
-Tu S, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ, Journal of Clinical Oncology 2009 May; JCO.2008.20.5393v1
Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer
-Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, et. al., Journal of Clinical Oncology 2009 May; 27:2429-2435
Quadramet Publications:
Samarium-153-lexidronam Complex for Treatment of Painful Bone Metastases in Hormone-Refractory Prostate Cancer (PDF 265KB)
- Sartor O, Reid RH, Hoskin PJ, et al. Urology. 2004;63:940-945
- The results of this study demonstrated that Samarium-153-lexidronam (153Sm-lexidronam) is safe and effective for the relief of the pain of bone metastases in patients with hormone-refractory prostate cancer.
Safety and Efficacy of Repeat Administration of Samarium Sm-153 Lexidronam to Patients With Metastatic Bone Pain (PDF 191KB)
- Sartor O, Reid RH, Bushnell DL, et al. Cancer. 2007;109:637-643.
- Repeated administration of Sm-153 is both efficacious and well tolerated in the treatment of bone pain and adverse events did not increase with repeat dosing of Sm-153.
Palliation of Pain Associated With Metastatic Bone Cancer Using Samarium-153 Lexidronam: A Double-Blind Placebo-Controlled Clinical Trial (PDF 193KB)
- Serafini AN, Houston SJ, Resch I, et al. J Clin Oncol. 1998;16:574-1581.
- A single intravenous dose of 1.0 mCi/kg of 153Sm-EDTMP provided efficacy with relatively mild and reversible hematologic effects in patients with pain associated with bone metastases.
A Dose-Controlled Study of 153Sm-Ethylenediaminetetramethylenephosphonate (EDTMP) in the Treatment of Patients With Painful Bone Metastases (PDF 167KB)
- Resche I, Chatal J-F, Pecking A, et al. Eur J Cancer. 1997;33:1583-1591.
- The 1.0 mCi/kg dose was found to be safe and effective for the treatment of painful bone metastases. Excellent efficacy and well-defined toxicity may make 153Sm-EDTMP appropriate for use in earlier stages of treatment of metastases.
Samarium for Osteoblastic Bone Metastases and Osteosarcoma (PDF 1MB)
- Anderson P. Expert Opin. Pharmacother. (2006) 7(11):1475-1486.
- The data presented indicate that 153Sm-EDTMP in standard doses (0.5 - 2.5 mCi/kg) is an easy-to-administer cancer treatment that has high osteoblastic bone lesion uptake and a very favorable side-effect profile.
News Releases
Please click here for a complete listing of news releases from the EUSA Pharma corporate site
REFERENCES:
- Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.
